Data Sheet

Product Name: Pamiparib  
Cat. No.: CS-0027388  
CAS No.: 1446261-44-4  
Molecular Formula: C16H15FN4O  
Molecular Weight: 298.31  
Target: PARP  
Pathway: Cell Cycle/DNA Damage; Epigenetics  
Solubility: DMSO : 62.5 mg/mL (209.51 mM; Need ultrasonic)

BIOLOGICAL ACTIVITY:

Pamiparib (GBG-290) is an orally active, potent, highly selective PARP inhibitor, with IC₅₀ values of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively. Pamiparib has oral bioavailability, potent PARP trapping, and capability to penetrate the brain, and can be used for the treatment of various cancers including the solid tumor[1][2]. IC₅₀ & Target: PARP[1]  
In Vitro: Pamiparib shows potent DNA-trapping activity with an IC₅₀ of 13 nM. In the cellular assays, Pamiparib inhibits intracellular PAR formation with an IC₅₀ of 0.24 nM. Tumor cell lines with homologous recombination defects are profoundly sensitive to Pamiparib. Pamiparib is highly active both in vitro and in vivo in BRCA mutant tumors[3].  

References:


CAIndexNames:
5,6,7a,11-Tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one, 2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)-

SMILES:
O=C1NN=c2C2N(C(C@@)(CC3)(C(C@)N4)C2C5=C4C=C(F)C=C51

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 732-484-9848  Fax: 888-484-5008  E-mail: sales@ChemScene.com  
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA